Treatment options for pancreatic neuroendocrine tumors (PNETs) have expanded considerably based on data from pivotal trials such as RADIANT-3 (NCT00510068), 1 Study A6181111 (NCT0 ...
(RTTNews) - Ipsen (IPSEY) announced confirmation of an expanded collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine ...
Pancreatic cancer accounts for a disproportionate number of cancer-related deaths relative to its incidence, reflecting its aggressive biology and limited treatment options. Most cases are exocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results